Press Releases

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 2a study at The Liver Meeting Digital ExperienceTM 2020, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 13-16, 2020.

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced positive data based on prespecified analyses of additional endpoint data from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in patients with cirrhosis and evidence of mild cognitive impairment consistent with hepatic encephalopathy.

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced results based on initial review of the topline data set from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in hepatic encephalopathy.